High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients.
In April 1988 the Christie Hospital started using the microSelectron-HDR machine to deliver intraluminal radiotherapy (ILT) to inoperable bronchial carcinomas causing symptoms due to endobronchial disease. Results of treatment in the first 406 patients with primary non-small-cell carcinoma are presented. Three main categories of patient were defined. Category 1 consisted of 324 patients (79.8%) who were previously unirradiated and received a single fraction of ILT as their primary treatment, mostly to a dose of 1500 cGy (76%) or 2000 cGy (23%) at 1 cm from the centre of the iridium-192 treatment source. The percentage of these patients whose symptoms or signs were improved at 6 weeks following ILT were as follows: stridor 92%, haemoptysis 88%, cough 62%, dyspnoea, 60%, pain, 50% and pulmonary collapse, 46%. Approximately two-thirds of these patients (67.3%) derived long lasting palliation and required no further treatment during their lifetime. The other third of patients needed subsequent treatment at some stage because of recurrence of their symptoms and in this situation external beam radiotherapy (EB) or a repeat ILT treatment was effectively utilised. Category 2 consisted of 65 patients (16%) who had previously received EB but required ILT when their tumour recurred. At 6 weeks post-ILT levels of symptom palliation were broadly similar to those obtained if ILT was used in previously unirradiated individuals, although the improvement was not so well sustained with time and only 7% showed improvement in pulmonary collapse at 6 weeks. Category 3 consisted of 17 patients (4.2%) in whom ILT was used concurrently with EB as a combined initial treatment. Similar levels of palliation were seen when compared with patients who received a single ILT treatment only. Overall, ILT was well tolerated in terms of early and late morbidity. In conclusion, the efficiency of a single ILT treatment in palliating symptoms due to endobronchial tumour in previously unirradiated individuals is comparable with that reported in series where treatment for advanced lung cancer combines a prolonged course of EB concurrently with several ILT treatments.
Gollins
S W
SW
Department of Radiotherapy, Christie Hospital, Withington, Manchester, UK.
Burt
P A
PA
Barber
P V
PV
Stout
R
R
D000368:Aged; D001918:Brachytherapy; D001984:Bronchial Neoplasms / Q000532:radiotherapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002423:Cause of Death; D003371:Cough / Q000532:radiotherapy; D004417:Dyspnea / Q000532:radiotherapy; D005260:Female; D005500:Follow-Up Studies; D006469:Hemoptysis / Q000532:radiotherapy; D006801:Humans; D007496:Iridium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D008175:Lung Neoplasms; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D010146:Pain / Q000532:radiotherapy; D010166:Palliative Care; D001261:Pulmonary Atelectasis / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D012135:Respiratory Sounds / Q000528:radiation effects; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D007496:Iridium Radioisotopes